| HOME >> BIOLOGY >> TECHNOLOGY |
IRVINE, Calif., June 24 /PRNewswire/ -- Stason Pharmaceuticals, Inc., a vertically integrated cGMP contract development organization announced today that it has appointed Diana Wood as Vice President, Business Development. Ms. Wood will be responsible for all business development functions, including guiding Stason's global business development activities. Ms. Wood is a senior executive with extensive experience in sales, marketing, business and strategic planning, product development and general management on a worldwide basis. She will report directly to Chief Executive Officer Harry T. Fan. Most recently, Diana Wood served as the Executive Vice President, Business Development at Chiltern International, Inc., where she oversaw the company's global business development and marketing functions, and advised clients on their product development platforms. Prior to joining Chiltern International, Ms. Wood served as the Director, Product Development for Oncology at Chugai Pharma USA in San Diego.
"We are pleased to welcome Diana to Stason," said Mr. Fan. "As a seasoned business development executive, she has built a highly respected track record and earned the trust of the pharmaceutical community. Diana will be a strategically important asset to our company. Furthermore, by bringing an extensive knowledge of the pharmaceutical industry and its regulatory environment combined with confidence and multifaceted business experience, she will continue to broaden and strengthen our relationship with our drug development partners."
"I am delighted to join Stason, a fast-growing and forward thinking
organization," Ms. Wood said. "Today's product development landscape is
changing rapidly and paradigms are shifting towards a more technologically
driven development process from the bench to market. Stason embraced these
changes early on, reducing overall development time and costs. I look
forward to bringing new opportunities to Stason and to further expand ou
'/>"/>
| SOURCE Stason Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
2. Renhuang Pharmaceuticals, Inc. Announces Solid Fourth Quarter and Fiscal Year 2007 Results
3. American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc.
4. AMAG Pharmaceuticals, Inc. and 3SBio, Inc. Announce Strategic Partnership to Develop and Commercialize Ferumoxytol in China
5. Jazz Pharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
6. Medimetriks Pharmaceuticals, Inc. Begins Operations
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
8. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
10. Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008
11. Aida Pharmaceuticals, Inc. Announces Update on Progress of Rh-Apo2L Testing
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |